Marek’s disease virus (MDV) can cause severe immunosuppression in chickens. Our previous study showed that infection with very virulent plus (vv+) MDV strains of one-day-old commercial meat-type chickens possessing maternal antibodies against MDV resulted in severe depletion of splenocytes at 28–30 days of age. In the present study, we have investigated the effect of vv+MDV strain 686 on splenic immunophenotypes at 6, 20, and 30 days post-infection (dpi). Both live and dead cells were analyzed, and the data were statistically compared to the uninfected control. The results revealed a decrease in the total live cell population starting on day 20, primarily affecting B cells, CD8β+, and gamma delta (γδ) T cells, while the frequencies of both live and dead CD3+ and CD4+ T cells were increased. The MHC-I expression of CD3+ and CD4+ T cells was higher at 20 and 30 dpi, while the expression of MHC-II on these cells was downregulated at 6 dpi but was upregulated at 30 dpi. Collectively, these results suggest that maternal antibodies seem to delay the negative effects of vv+MDV on the splenic lymphoid populations, albeit being non-protective. Our results emphasize the importance of MD vaccination in vv+MDV endemic areas.
Very virulent plus Marek’s disease virus (vv+MDV) induces severe immunosuppression in commercial chickens. In this study, we evaluated how three Gallid alphaherpesvirus 2 (GaHV-2) vaccines (CVI-988, rMd5-BAC∆Meq, and CVI-LTR) protected against two negative outcomes of vv+MDV infection: (1) reduced viability and frequency of immune cells in the spleen and (2) decreased efficacy of the CEO (chicken embryo origin) vaccine against infectious laryngotracheitis challenge. At 25 days post-infection with vv+MDV 686, all vaccines are protected against the reduced viability of splenocytes. However, there were differences in the frequency of splenic immunophenotypes among groups. Compared to the uninfected control, the frequency of B cells was reduced in the CVI-988/686 group but not in the rMd5-BAC∆Meq/686 and CVI-LTR/686 groups. T cell subset frequencies showed no difference between the negative controls and CVI-988/686; however, there was a reduction in activated CD4+ T cells in the rMd5-BAC∆Meq/686 group and in activated CD4+, activated CD8+, and γδ+ T cells in the CVI-LTR/686 group. We also demonstrated that the three vaccines protected against MDV-induced tumors, but only rMd5-BAC∆Meq and CVI-LTR protected against the negative impact of vv+MDV 648A strain on CEO vaccine efficacy. Our findings demonstrate important differences in the biology and/or mechanisms of protection of these vaccines.
High load of oncogenic Marek's disease virus (MDV) DNA in the feather pulp (FP) as early as 21 days of age is a powerful criterion to predict the outcome of Marek's disease (MD) in apparently healthy chickens. The objective of this study was to elucidate the immunopathological changes in the FP of 21-days-old chickens that had been vaccinated with CVI988 vaccine (healthy), vaccinated and challenged with a very virulent plus (vv+) MDV strain 648A (well protected), or were unvaccinated and challenged with 648A strain (not protected) when compared to non-infected naïve chickens. Oncogenic MDV DNA load, histopathological and immunohistochemical evaluation of the lesions, and immunophenotypic characterization of the infiltrates by flow cytometry was conducted. Our results demonstrate that 648A infected non-vaccinated chickens had a significant increase in the percentage of CD3+ T cells, mainly CD4 + MHC-II + cells and CD8 + MHC-II + cells, when compared to all other groups. They also had a significantly decreased number of CD8β+ T cells compared to all other groups. Infection with 648A reduced the percentage of macrophages not only in the unvaccinated group but also in the CVI988/648A group. In addition, groups that were vaccinated with CVI988, regardless of the challenge status, had higher levels of CD8β+ T cells, suggesting that the vaccine has an enhancing effect on the CTL cells. Our results showed that the load of oncogenic MDV is highly correlated with the infiltration of CD4 + MHC-II + cells and provide further confirmation that FP is indeed an appropriate sample for the early diagnosis of MD.
Very virulent plus (vv+) Marek's disease virus (MDV) strains are highly immunosuppressive and cause marked alterations in splenic immune cell populations in commercial meat-type (MT) chickens, even in the presence of maternal antibodies. In this study, we evaluated the protection provided by a recombinant herpesvirus of turkeys (rHVT) vaccine delivered at either a standard dose (SD) or a high dose (HD) against splenocyte damage induced by the vv + MDV strain 686 in MT chickens. Results showed that both rHVT-SD and rHVT-HD protected against the 686-induced reduction in splenocyte lymphoproliferative responses to concanavalin A (ConA) ex vivo and modestly, albeit not significantly, reduced 686 replication in the spleen at 6 days post-infection (dpi). However, by 25 dpi, neither vaccine dose limited the 686 DNA load in the spleen. Protection against splenic immunophenotypic alterations at 25 dpi was suboptimal; neither rHVT-SD nor rHVT-HD prevented the reduction in the number of live splenocytes, B cells, or KUL01+MHC-IIhigh+ APCs. However, modest improvements were observed; the rHVT-SD/686 group showed slightly higher percentages of live splenocytes and B cells than the 686-infected group, whereas the rHVT-HD/686 group exhibited a numerical increase only in B cells. Furthermore, rHVT vaccination influenced the percentage of activated T cells. Both rHVT-SD and rHVT-HD vaccinations decreased the percentage of activated CD4+ T cells. The percentage of activated CD8α+ T cells was also reduced in both vaccine groups, but the reduction was significant only in the HD group, whereas the proportion of activated CD8β+ T cells decreased only in the SD-vaccinated group. In addition, both vaccine doses reduced the percentage of γδ+ T cells. Overall, our findings demonstrate that vaccination with rHVT provided partial protection against vv + MDV 686-induced immunophenotypic changes in the spleen, with no added benefit from using a higher rHVT-vaccine dose.